HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples

被引:398
作者
Rai, AJ
Gelfand, CA
Haywood, BC
Warunek, DJ
Yi, JZ
Schuchard, MD
Mehigh, RJ
Cockrill, SL
Scott, GBI
Tammen, H
Schulz-Knappe, P
Speicher, DW
Vitzthum, F
Haab, BB
Siest, G
Chan, DW
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Clin Chem, Baltimore, MD 21287 USA
[2] BD Diagnost, Franklin Lakes, NJ USA
[3] Sigma Aldrich Biotechnol, St Louis, MO USA
[4] BioVisioN AG, Hannover, Germany
[5] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[6] Dade Behring Marburg GmbH, Marburg, Germany
[7] Van Andel Res Inst, Grand Rapids, MI USA
[8] Univ Nancy 1, Fac Pharm, INSERM, Equipe 4,U525, Nancy, France
关键词
plasma; specimen collection and handling;
D O I
10.1002/pmic.200401245
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
There is a substantial list of pre-analytical variables that can alter the analysis of blood-derived samples. We have undertaken studies on some of these issues including choice of sample type, stability during storage, use of protease inhibitors, and clinical standardization. As there is a wide range of sample variables and a broad spectrum of analytical techniques in the HUPO PPP effort, it is not possible to define a single list of pre-analytical standards for samples or their processing. We present here a compendium of observations, drawing on actual results and sound clinical theories and practices. Based on our data, we find that (1) platelet-depleted plasma is preferable to serum for certain peptidomic studies; (2) samples should be aliquoted and stored preferably in liquid nitrogen; (3) the addition of protease inhibitors is recommended, but should be incorporated early and used judiciously, as some form non specific protein adducts and others interfere with peptide studies. Further, (4) the diligent tracking of pre-analytical variables and (5) the use of reference materials for quality control and quality assurance, are recommended. These findings help provide guidance on sample handling issues, with the overall suggestion being to be conscious of all possible pre-analytical variables as a prerequisite of any proteomic study.
引用
收藏
页码:3262 / 3277
页数:16
相关论文
共 38 条
[1]   MANUFACTURE AND CHARACTERIZATION OF A NEW REFERENCE PREPARATION FOR 14 PLASMA-PROTEINS CRM-470=RPPHS LOT-5 [J].
BAUDNER, S ;
HAUPT, H ;
HUBNER, R .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1994, 8 (04) :177-190
[2]  
Buttner J, 1995, EUR J CLIN CHEM CLIN, V33, P981
[3]   Proteomics and cancer - Running before we can walk? [J].
Check, E .
NATURE, 2004, 429 (6991) :496-497
[4]   Mass Spectrometry as a diagnostic and a cancer biomarker discovery tool - Opportunities and potential limitations [J].
Diamandis, EP .
MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (04) :367-378
[5]   Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing [J].
Favaloro, EJ ;
Soltani, S ;
Mcdonald, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (05) :686-692
[6]   PREFERENTIAL HYDRATION OF BOVINE SERUM-ALBUMIN IN POLYHYDRIC ALCOHOL-WATER MIXTURES [J].
GEKKO, K ;
MORIKAWA, T .
JOURNAL OF BIOCHEMISTRY, 1981, 90 (01) :39-50
[7]  
Görg A, 1999, ELECTROPHORESIS, V20, P712
[8]   National Heart, Lung, and Blood Institute Clinical Proteomics Working Group report [J].
Granger, CB ;
Van Eyk, JE ;
Mockrin, SC ;
Anderson, NL .
CIRCULATION, 2004, 109 (14) :1697-1703
[9]   Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin [J].
Gupta, CK ;
Leszczynski, J ;
Gupta, RK ;
Siber, GR .
VACCINE, 1996, 14 (15) :1417-1420
[10]  
HAAB BB, 2005, PROTEOMICS, V5, DOI DOI 10.1002/PMIC.200400470